Your browser doesn't support javascript.
Interleukin-13: A pivotal target against influenza-induced exacerbation of chronic lung diseases.
Shastri, Madhur D; Allam, Venkata Sita Rama Raju; Shukla, Shakti D; Jha, Niraj Kumar; Paudel, Keshav Raj; Peterson, Gregory M; Patel, Rahul P; Hansbro, Philip M; Chellappan, Dinesh K; Dua, Kamal.
  • Shastri MD; School of Pharmacy and Pharmacology, University of Tasmania, Hobart 7005, Australia. Electronic address: Madhur.Shastri@utas.edu.au.
  • Allam VSRR; Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
  • Shukla SD; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, Australia; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.
  • Jha NK; Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida, UP, India.
  • Paudel KR; Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney, NSW 2007, Australia.
  • Peterson GM; School of Pharmacy and Pharmacology, University of Tasmania, Hobart 7005, Australia.
  • Patel RP; School of Pharmacy and Pharmacology, University of Tasmania, Hobart 7005, Australia.
  • Hansbro PM; Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney, NSW 2007, Australia.
  • Chellappan DK; Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Kuala Lumpur, Malaysia.
  • Dua K; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney,
Life Sci ; 283: 119871, 2021 Oct 15.
Article in English | MEDLINE | ID: covidwho-1336712
ABSTRACT
Non-communicable, chronic respiratory diseases (CRDs) affect millions of individuals worldwide. The course of these CRDs (asthma, chronic obstructive pulmonary disease, and cystic fibrosis) are often punctuated by microbial infections that may result in hospitalization and are associated with increased risk of morbidity and mortality, as well as reduced quality of life. Interleukin-13 (IL-13) is a key protein that regulates airway inflammation and mucus hypersecretion. There has been much interest in IL-13 from the last two decades. This cytokine is believed to play a decisive role in the exacerbation of inflammation during the course of viral infections, especially, in those with pre-existing CRDs. Here, we discuss the common viral infections in CRDs, as well as the potential role that IL-13 plays in the virus-induced disease pathogenesis of CRDs. We also discuss, in detail, the immune-modulation potential of IL-13 that could be translated to in-depth studies to develop IL-13-based therapeutic entities.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-13 / Influenza, Human / Lung Diseases Type of study: Prognostic study Limits: Humans Language: English Journal: Life Sci Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-13 / Influenza, Human / Lung Diseases Type of study: Prognostic study Limits: Humans Language: English Journal: Life Sci Year: 2021 Document Type: Article